Callan JMB Inc. 与 Attune 签署制造监督、联邦部署及多资产治疗管线商业化协议,预计总收入达5000万至7500万美元
美股速递
Jan 15
Callan JMB Inc. 已与生物技术公司 Attune 达成一项重要合作协议,内容涵盖多资产治疗管线的制造监督、联邦部署及商业化安排。该协议预计将为 Callan JMB Inc. 带来约5000万至7500万美元的总收入。
根据协议,Callan JMB Inc. 将负责监督相关治疗产品的生产流程,并协助推进其在美国联邦层面的部署与应用。双方还将共同推动治疗管线的商业化进程,覆盖多个疾病领域。
此次合作不仅有望为 Callan JMB Inc. 创造可观收入,也将进一步拓展其在生物制药领域的业务布局,提升企业整体竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.